Company Overview
Vitadio pioneers prescription digital therapeutics focusing on reversing insulin resistance through AI-driven lifestyle modification.
Our Purpose
Vitadio empowers people to restore their cardiometabolic health by creating digital therapies that treat the cause, not just the symptoms, with a focus on habit change without side effects.
Clinical Impact
The clinical effect of Vitadio's digital therapeutics is comparable to modern antidiabetic drugs. Rigorous validation through clinical studies shows superior HbA1c reduction and significant weight loss among patients using their therapy.
Platform Features
Vitadio offers personalised therapy with smart nudges and goals, AI-driven real-time diet feedback, and proactive human support including social networking and personal dietitian access.
History and Expansion
Founded in 2019, Vitadio is headquartered in Prague and Berlin, providing digital therapeutics for type 2 diabetes and prediabetes across three European countries with ongoing expansion.
Partners and Collaborations
Vitadio collaborates with major pharmaceutical companies like AstraZeneca and Novo Nordisk, augmenting pharmacotherapy with their digital therapeutics to improve clinical outcomes and patient adherence.
Job Opportunities
Vitadio is hiring passionate individuals to join their purpose-driven team tackling healthcare challenges. Career opportunities are listed on their website.